A 12-week randomized, double-blind, vehicle-controlled trial of RLX-201, the active compound in Re-Q Longevity Face Serum, has been published in the Journal of Cosmetic Dermatology. Across 47 women aged 35 to 65 with moderate-to-severe photoaging, the company reports improvements in investigator-assessed firmness and cheek wrinkles of 21% from baseline at Week 12, with instrumented elastometry indicating improved viscoelastic properties from Week 8 onward and no adverse events in either arm.
Key Points
- Vehicle-controlled trial in 47 women with moderate-to-severe facial photoaging
- Firmness and cheek wrinkles improved 21% from baseline by Week 12
- Elastometry gains peaked at Week 8; no adverse events reported
Longevity Analysis
Skin is the body's largest barrier organ, and its mechanical properties track collagen turnover, hydration status and cumulative photo-oxidative load rather than chronological age alone. Instrumented elastometry moves topical assessment beyond subjective grading toward a measurable readout of dermal regeneration, which is what makes a vehicle-controlled design meaningful here. The applied benefit still depends on twice-daily adherence over months and on reducing the ultraviolet and oxidative exposure driving the damage in the first place.
Original published by LT Wire.